Navigation Links
Solace Therapeutics, Inc. Announces CE Mark Approval

FRAMINGHAM, Mass., Oct. 1 /PRNewswire/ -- Solace Therapeutics, Inc., a medical device company focused on the development of non-surgical bladder control therapies announced today that it has received European CE mark approval for the Solace Intravesical System, and ISO 13485:2003 certification for the company's Framingham facility. The company is introducing its first product, an office-based therapy for Female Stress Urinary Incontinence at the International Continence Society Meeting in San Francisco on Friday, October 2, 2009.

"This certification and CE mark approval represent a significant achievement and major milestone for Solace," said Kevin Connors, chief executive officer of Solace Therapeutics. "Successfully completing this process allows us to move forward with the clinical development of the Solace Intravesical System in Europe.

Solace is introducing its first product, a non-surgical therapy for women with Stress Urinary Incontinence, to ICS members at their annual meeting on Friday. "Solace is targeting those patients that are dissatisfied with current therapies and choose to manage their urinary leakage with absorbent pads or diapers," said Connors. "Solace has developed a new option for these patients."

The Solace Balloon is a small lightweight device (about the size of a quarter) that floats within the urinary bladder. It acts as a "shock absorber" to reduce the temporary pressure changes in the bladder that cause urinary leakage. It is placed in the bladder with a soft tube-like catheter and inflated with air. The 5 minute procedure is performed in the physician's office without anesthesia or surgery. No lifestyle change is required after the procedure, and the procedure is reversible at any time.

The Solace Balloon for women with involuntary urine leakage is currently being evaluated in several centers throughout the U.S. in an FDA IDE approved clinical trial. More information about the product is available at

About Solace Therapeutics

Solace Therapeutics is an emerging medical device company focused on the development of non-surgical office based treatments for common bladder disorders, such as stress urinary incontinence (SUI), overactive bladder (OAB), male voiding dysfunction and lower urinary tract symptoms (LUTS). Solace is dedicated to improving the patient's quality of life by eliminating side effects typically associated with current drug and surgical therapies. Solace's proprietary technology is designed to offer patients the following benefits:

  • Office-based therapy that does not require anesthesia or surgery
  • No lifestyle change required, before or after treatment
  • Reversible at any time

Solace's patented technology platform is based on the fundamental fluid mechanics principles of reducing rapid pressure changes in fluid with air-based pressure attenuation. Solace is the pioneer of applying these principles to treat bladder dysfunction. More information on Solace contact Kevin Connors at or visit

SOURCE Solace Therapeutics, Inc.

SOURCE Solace Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Solace Pharmaceuticals Initiates Phase IIa Trial of Glial Cell Modulator SLC022 in Post-Herpetic Neuralgia
2. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
3. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
4. Cell Therapeutics, Inc. (CTI) Supports Panel Discussion on Women and Lung Cancer on Capitol Hill
5. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
6. NIST Awards $2 Million to Velcura Therapeutics, Inc. for Innovative Technology R&D - Dual-Action Therapies for Bone Disease
7. Ocera Therapeutics, Inc. Completes Enrollment in FHAST1, a Pivotal Phase 3 Clinical Trial in Fistulizing Crohns Disease
8. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
9. Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM)
10. Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor
11. Cell Therapeutics, Inc. (CTI) Announces Enrollment Complete in Phase III EXTEND (PIX301) Clinical Trial of Pixantrone in Patients With Second or Greater Relapse of Diffuse Large B Cell NHL
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Surface Testing Market: Supplier Shares, Competitive ... offering.  --> ) ... "2016 Future Horizons and Growth Strategies ...
(Date:11/26/2015)... 26, 2015 ... adds "Global Repaglinide Industry 2015 ... on China Repaglinide Market, 2010-2019" reports ... and information to its online business ... . --> ...
(Date:11/25/2015)... 25, 2015 ... the "Global Brain Monitoring Devices Market ... --> ) has announced the ... Devices Market 2015-2019" report to their ... ( ) has announced the addition ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... Water For Empowerment ™ attracts volunteers together who want to combine talents ... women as key stakeholders in the process. The non-profit launched its first major ...
(Date:11/25/2015)... ... November 25, 2015 , ... Finnleo, a leader in the traditional ... models of traditional and far-infrared saunas. , For traditional saunas, Finnleo is ... traditional Finnish sauna wood, and Finnleo uses only European Grade A Nordic White Spruce ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... ... offering factory direct sauna parts and accessories. , Sauna accessories help improve ... the bather’s style and personality. From basic styles for the purist looking for ...
(Date:11/25/2015)... , ... November 26, 2015 , ... ... Commission (AUC), European Union (EU), ANDI Pan African Centres of Excellence, and public ... in Nairobi (UNON) for the opening of the 5th African Network for Drugs ...
(Date:11/25/2015)... ... ... For the first time, Vitalalert is donating half of its earnings to ... between the two groups began in 2014 with Vitalalert pledging a portion of every ... founded in 1954 and is an international Christian-based health organization whose mission is to ...
Breaking Medicine News(10 mins):